Medigene AG

Medigene presents posters on immunotherapies at CRI-CIMT-EATI-AACR Conference - Seite 2

TCR therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR T) therapy. Medigene is preparing the clinical development of its first TCR candidates and is establishing a pipeline of recombinant T cell receptors, and has established Good Manufacturing Practice (GMP)-compliant processes for their combination with patient-derived T cells.

Medigene's first TCR immunotherapy "MDG1011" will be tested in a clinical Phase I/II trial intended to be started by the end of 2017.

Besides the planned company-sponsored TCR trial, Medigene is involved in an investigator-initiated trial (IIT) with TCRs in multiple myeloma (MM) to be conducted by the Charité - Universitätsmedizin Berlin in cooperation with the Max Delbrück Centre (MDC), Berlin.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with projects currently in preclinical and clinical development.
For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: [e-mail]

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ([e-mail]). We will then delete your address from our distribution list.

(end)

emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg
country: Germany
contact person: Medigene PR/IR
phone: [phone]
e-mail: [e-mail]
website: www.medigene.de

ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20170816005 ]